Clinical trials: Phase I
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Tumors
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or…
- Trial name
- NCT00543231
- Testing
- G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Genta Incorporated
Leukemia, Myeloid, Acute
HDM201 Added to CT in R/R or Newly Diagnosed AML
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML.
- Trial name
- NCT03760445
- Testing
- HDM201, cytarabine, anthracycline
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to…
- Trial name
- NCT05601219
- Testing
- ADA-011, PD(L)-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Adanate, Inc
Healthy
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT06633419
- Testing
- Opevesostat, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants
A study to evaluate single and multiple ascending doses of experimental medicine BMS-986318 in healthy participants.
- Trial name
- NCT04082741
- Testing
- BMS-986318
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Infections, Meningococcal
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).
- Trial name
- NCT02639351
- Testing
- Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R, Investigational MenC-CRM adjuavnted with 25 ug of LHD153R, Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers
- Trial name
- NCT04232345
- Testing
- AZD4831
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Knee Osteoarthritis
Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis
The aim of this study is to assess the safety of Stemedica's mesenchymal stem cells in patients with knee osteoarthritis. The route of administration is intraarticular.
- Trial name
- NCT03602872
- Testing
- Human allogeneic mesenchymal bone marrow derived stem cells
- Where
- Mexico
- Sponsor
- Clinica Santa Clarita, Mexico
HIV
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
The purpose of this study is to investigate the pharmacokinetics of TMC278 (rilpivirine) 25 mg once daily following a preceding 2-week treatment period with efavirenz 600 mg once daily in healthy volunteers
- Trial name
- NCT01268839
- Testing
- TMC278, Efavirenz
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec, Inc
Liver Disease
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
This is an open-label study that will compare the pharmacokinetic and safety effects of naproxcinod in hepatic impaired patients vs. matching healthy subjects.
- Trial name
- NCT00621881
- Testing
- naproxcinod
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NicOx
Healthy Volunteers
A Study of ACE-2494 in Healthy Subjects
The purpose of the study is to assess safety, tolerance, pharmacokinetic, and pharmacodynamics of single doses of ACE-2494 in healthy postmenopausal women.
- Trial name
- NCT03478319
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Acute Myelogenous Leukemia
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a daily times 3 schedule in…
- Trial name
- NCT00486265
- Testing
- AZD4877
- Where
- 4 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants
The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.
- Trial name
- NCT04155567
- Testing
- TAK-123
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteers
A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole
This study will evaluate the effect of an acidic formulation of Acalabrutinib (ACP-196), acidic beverage, or grapefruit Juice on the PK of ACP-196 alone and coadministered with omeprazole.
- Trial name
- NCT04876807
- Testing
- ACP-196, Omeprazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Acerta Pharma BV
Solid Tumors
A Study of ZG005 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
- Trial name
- NCT06233292
- Testing
- ZG005 Powder for Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
SARS CoV-2
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
The goal of this clinical trial is to test the safety and tolerability of a single ascending dose (SAD) of GB-0669 administered intravenously in adults.
- Trial name
- NCT07050511
- Testing
- GB-0669
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Generate Biomedicines
Neoplasms, Neoplasm Metastasis
A Study of LY3039478 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma.
- Conditions
- Neoplasms, Neoplasm Metastasis, Lymphoma
- Trial name
- NCT01695005
- Testing
- LY3039478, Prednisone
- Where
- 11 sites in United States, Denmark and 4 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects
The primary purpose of this study is to evaluate pharmacokinetic comparability of 1x30 mg pegvisomant injection administered as a single 1 mL injection versus 2x15 mg/mL pegvisomant administered as two separate 1 mL injections…
- Trial name
- NCT01893866
- Testing
- 1 x 30 mg/mL pegvisomant, 2 x 15 mg/mL pegvisomant
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.